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Numerous disorders of the central nervous system (CNS) are attributed to the selective
death of distinct neuronal cell populations. Interestingly, in many of these conditions,
a specific subset of neurons is extremely prone to degeneration while other, very
similar neurons are less affected or even spared for many years. In Parkinson’s disease
(PD), the motor manifestations are primarily linked to the selective, progressive loss of
dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). In contrast,
the very similar DA neurons in the ventral tegmental area (VTA) demonstrate a much
lower degree of degeneration. Elucidating the molecular mechanisms underlying the
phenomenon of differential DA vulnerability in PD has proven extremely challenging.
Moreover, an increasing number of studies demonstrate that considerable molecular and
electrophysiologic heterogeneity exists among the DA neurons within the SNpc as well
as those within the VTA, adding yet another layer of complexity to the selective DA
vulnerability observed in PD. The discovery of key pathways that regulate this differential
susceptibility of DA neurons to degeneration holds great potential for the discovery
of novel drug targets and the development of promising neuroprotective treatment
strategies. This review provides an update on the molecular basis of the differential
vulnerability of midbrain DA neurons in PD and highlights the most recent developments
in this field.
Keywords: Parkinson’s disease, substantia nigra, ventral tegmental area, dopamine, selective vulnerability,
differential vulnerability
INTRODUCTION
The selective death of distinct neuronal cell populations is the key
feature of many disorders of the central nervous system (CNS).
The identity of the affected neurons as well as the pattern of
neuronal degeneration are specific to the respective disorder and
determine the clinical signs that are typically associated with the
condition. Examples of diseases that are characterized by the
selective degeneration of neurons in the CNS include Alzheimer’s
disease, Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis
(ALS) and autosomal recessive proximal Spinal Muscular Atro-
phy. It is largely unknown why different groups of neurons are
highly vulnerable to degeneration in different diseases. Moreover,
it is unclear why, in a particular condition, some neurons are
extremely prone to degeneration while other, very similar neu-
rons are spared over years. In early Alzheimer’s disease, distinct
subgroups of neurons in layer II of the entorhinal cortex, the
subiculum, and the CA1 region of the hippocampus are par-
ticularly vulnerable to degeneration, while many other cortical
and hippocampal regions do not show pathological signs at this
disease stage (Morrison and Hof, 2002, 2007; Stranahan and
Mattson, 2010). Amyotrophic Lateral Sclerosis affects both upper
and lower motor neurons (Boillée et al., 2006; Talbot, 2014).
However, cortical, spinal and lower cranial nerve motor neu-
rons undergo degeneration early in the disease, while the motor
neurons of Onuf ’s nucleus, as well as the oculomotor, trochlear
and abducens nerves remain largely unaffected from cell loss even
at late disease stages (Alexianu et al., 1994; Kihira et al., 1997; von
Lewinski and Keller, 2005). Autosomal recessive proximal spinal
muscular atrophy is characterized by the progressive selective
loss in particular of the lower motor neurons in the anterior
horns of the spinal cord, while upper motor neurons are spared
(Talbot and Davies, 2001). In PD, the motor manifestations
are primarily linked to the selective loss of dopaminergic (DA)
neurons in the substantia nigra pars compacta (SNpc; Brichta
et al., 2013). In contrast, the very similar DA neurons in the
ventral tegmental area (VTA) demonstrate a higher degree of
resistance to degeneration (Dauer and Przedborski, 2003). Our
current knowledge about the determinants of the differential
vulnerability of SNpc and VTA DA neurons in PD is still extremely
limited. Undoubtedly, discovery of the factors that mediate this
differential vulnerability would have far-reaching implications for
the development of promising neuroprotective strategies and the
treatment of PD. This review provides an update on the molecular
basis of the differential vulnerability of midbrain DA neurons in
PD. We will focus on the most recent developments in this field
and discuss these data in the light of previous findings and also
regarding their relevance in explaining different aspects of the
pattern of DA cell loss in PD.
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MIDBRAIN DA NEURONS AND THEIR DIFFERENTIAL
VULNERABILITY IN PD
The largest groups of DA neurons in the midbrain are located in
very close proximity to each other in the SNpc (A9 group) and in
the VTA (A10 group). SNpc and VTA DA neurons represent two
of the nine major DA neuron groups in the mammalian brain as
identified by staining for tyrosine hydroxylase (TH), the enzyme
that catalyzes the rate-limiting step in the synthesis of dopamine
(Björklund and Dunnett, 2007). In mice and rats, considerably
fewer DA neurons are found in the midbrain than in monkeys
and humans (Figure 1). Moreover, while SNpc and VTA contain
comparable numbers of DA neurons in mice and rats, SNpc DA
neurons outnumber VTA DA neurons in monkeys and humans.
The variations among the reported counts of TH-positive neurons
in the SNpc and the VTA for a specific species may at least in part
be due to interindividual differences between study subjects, but
are most likely the result of different statistical methods that were
applied to calculate the total number of DA neurons in the two
midbrain nuclei. In addition to the DA neurons, both SNpc and
VTA also contain a considerable number of GABAergic neurons,
while only a very few glutamatergic neurons are present whose
location is mainly restricted to the VTA (Nair-Roberts et al.,
2008).
SNpc DA neurons are heavily involved in the control of move-
ment, whereas VTA DA neurons are responsible for the regulation
of reward, emotional behavior and addiction. Both groups of
neurons are characterized by distinct but overlapping projection
patterns that have been extensively investigated in numerous
tracing studies (comprehensively reviewed in (Bentivoglio and
Morelli, 2005)). The majority of projections that originate from
SNpc DA neurons innervate the dorsal striatum, and only some
nigral fibers project to the ventral striatum and the cortex. In
contrast, VTA DA neurons mainly project to the ventral striatum
as well as cortical areas, while significantly fewer projections
innervate the dorsal striatum. Both SNpc and VTA DA neurons
send minor projections to additional brain regions including
the globus pallidus, the subthalamic nucleus, and the habenula.
Moreover, a minority of DA projections originating in the VTA
projects to the amygdala. DA neurons located in the midbrain
also sparsely innervate distinct hippocampal regions. The density
of the DA innervation of a distinct brain region often varies
significantly between different species. Interestingly, anatomic
differences in the DA projection sites correlate with several dis-
similarities observed in DA neuron function. A combination
of retrograde tracing, electrophysiological and basic molecular
studies in mice demonstrated that distinct subgroups of VTA
and SNpc DA neurons in confined midbrain territories project to
specific striatal, cortical and limbic target regions, and these neu-
rons can be distinguished by their expression levels of dopamine
transporter (DAT), their electrophysiological properties and their
capacities for dopamine D2 autoreceptor signaling (Lammel et al.,
2008).
Despite the fact that SNpc and VTA DA neurons generate,
store and release the same neurotransmitter, that their cell bodies
in the midbrain are localized in close proximity to each other,
and that significant overlap exists in the brain areas that are
innervated by the projections of these neurons, SNpc and VTA
FIGURE 1 | Number of SNpc and VTA DA neurons in humans,
monkeys, rats and mice. In adult C57BL/6 mice, approximately
8,000–12,000 TH-positive neurons are located in each of the two neuron
groups bilaterally (German et al., 1996; Nelson et al., 1996; Jackson-Lewis
and Przedborski, 2007). Studies in rats revealed about 21,000–25,000
TH-positive neurons in the SNpc and about 20,000–40,000 TH-positive
neurons in the VTA bilaterally (German and Manaye, 1993; Nair-Roberts
et al., 2008). In monkeys and humans, much higher numbers of DA neurons
are found in the midbrain. Stereology studies counted approximately
120,000–270,000 TH-positive neurons bilaterally in the SNpc and about
110,000 TH-positive neurons bilaterally in the VTA in rhesus and squirrel
monkeys (Emborg et al., 1998; McCormack et al., 2004; Collier et al., 2007;
Kanaan et al., 2007). In humans, about 200,000–420,000 TH-positive
neurons bilaterally were reported for the SNpc in adults and about
60,000–65,000 TH-positive neurons for the VTA (Hirsch et al., 1988;
McRitchie et al., 1997; Damier et al., 1999a; Chu et al., 2002).
DA neurons exhibit a different susceptibility to degeneration in
PD. The DA neurons in the SNpc are highly vulnerable to the fatal
molecular mechanisms associated with the disease. Along with the
formation of alpha-synuclein-rich intraneuronal protein aggre-
gates termed Lewy Bodies in various brain regions (Spillantini
et al., 1997; Braak et al., 2003; Burke et al., 2008), the progressive
loss of pigmented SNpc DA neurons is a pathological hallmark
of PD (Brichta et al., 2013). Calculations of the number of DA
neurons (as identified by the expression of TH) in post-mortem
tissue from patients with advanced idiopathic (non-genetic) PD
and control subjects revealed that, on average, almost 80% of all
SNpc DA neurons undergo degeneration in PD (Hirsch et al.,
1988; Damier et al., 1999b). DA cell loss is most severe in the
ventrolateral part of the SNpc (Halliday et al., 1996; Damier
et al., 1999b; Braak et al., 2003), which was also unequivocally
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demonstrated in a more current study that investigated a large set
of post-mortem brain samples obtained from patients with PD
(Kordower et al., 2013). These data show that DA cell loss in the
SNpc follows a specific pattern and suggest that subtle molecular
differences exist among subgroups of SNpc DA neurons. In con-
trast to SNpc DA neurons, the very similar DA neurons in the
VTA are more resistant to degeneration. In their studies, Damier
et al. and Hirsch et al. analyzed the number of both SNpc and VTA
DA neurons, providing cell counts that can be directly compared
with each other due to the investigation of the same midbrain
tissue samples and the application of the same statistical methods.
The average loss of VTA DA neurons observed in patients with
advanced idiopathic PD as compared to unaffected controls was
estimated to be only about 50% which is a much lower percentage
of DA neuron loss than in the SNpc (Hirsch et al., 1988; Damier
et al., 1999b). These data strongly suggest that specific modifiers
partially protect VTA DA neurons from degeneration as compared
to SNpc DA neurons, and/or that specific modifiers increase the
vulnerability of SNpc DA neurons to PD-associated cell loss as
compared to VTA DA neurons.
PD can be caused by non-genetic or genetic factors (Cookson
and Bandmann, 2010; Houlden and Singleton, 2012; Hirsch et al.,
2013; Singleton et al., 2013). However, differential vulnerabil-
ity among midbrain DA neurons is observed regardless of the
disease etiology. Neuropathological findings in published cases
with various genetic forms of PD include loss of SNpc DA
neurons without describing VTA DA neuron degeneration (Mori
et al., 1998; Spira et al., 2001; Gouider-Khouja et al., 2003; Farrer
et al., 2004; Zarranz et al., 2004; Zimprich et al., 2004; Pramstaller
et al., 2005; Hasegawa et al., 2009). Thus, it is reasonable to con-
clude that differential DA neuron vulnerability does not depend
on the factor triggering PD, but is based on slightly varying
intrinsic properties of subgroups of these neurons.
COMPARATIVE EXPRESSION PROFILING OF SNPC AND VTA
DA NEURONS
A highly promising approach to identify intrinsic factors that
distinguish SNpc from VTA DA neurons and that mediate the
differential vulnerability of these neurons to degeneration in PD
is the comparative expression profiling of SNpc and VTA DA neu-
rons. Technologies such as laser-capture microdissection (LCM),
microarray and next-generation sequencing facilitate the isolation
of specific types of DA neurons and the characterization of their
gene expression profiles. Comparative expression profiling studies
in human brain samples are surprisingly rare. An early study
in post-mortem tissue samples from control subjects described
the isolation of DA neurons from several different brain regions
including the SNpc and the VTA and the subsequent generation
of cell-specific RNA expression profiles using a fingerprinting
approach (Lu et al., 2004). However, this investigation did not
go beyond the description of a methodological protocol and
did not provide a list of differentially expressed transcripts or
any functional analyses. Since then, several studies have focused
on the analysis of the gene expression profiles of laser-captured
SNpc DA neurons in patients with PD and control subjects,
but a comparison between SNpc and VTA DA neurons was not
pursued (Cantuti-Castelvetri et al., 2007; Simunovic et al., 2009;
Zheng et al., 2010). The lack of such comparative expression
profiling studies may be due to the fact that many brain banks
have difficulties providing tissue samples containing VTA DA
neurons. It is often standard protocol that donated brains are
crudely divided into the left and right hemispheres which are then
processed separately. Since VTA DA neurons are located along or
close to the midline, the tissue containing these neurons is often
destroyed.
In contrast to the lack of human studies, three different studies
have applied LCM in combination with microarray analysis to
compare the expression profiles of SNpc and VTA DA neurons
in rodents (Grimm et al., 2004; Chung et al., 2005; Greene et al.,
2005). Another comparative study was carried out by manually
dissecting whole SNpc and VTA followed by serial analysis of gene
expression (SAGE). However, the main goal of this analysis was
not the elucidation of transcripts that are differentially expressed
between SNpc and VTA, but rather the overall comparison of
the gene expression patterns of 11 different mouse brain regions
(Brochier et al., 2008). The rationale for these investigations was
that both SNpc and VTA are conserved between humans, mice
and rats. Moreover, the differential susceptibility of these two DA
neuron groups to degeneration in PD can be reproduced with the
neurotoxin MPTP in various animal models for PD (Seniuk et al.,
1990; Sirinathsinghji et al., 1992; Muthane et al., 1994; Varastet
et al., 1994; Jackson-Lewis et al., 1995). All three comparative
microarray analyses demonstrated that SNpc and VTA DA neu-
rons are closely related and only <1% (Grimm et al., 2004) or
<3% (Greene et al., 2005) of all detected genes were differentially
expressed. A functional analysis of the gene expression patterns
of SNpc and VTA DA neurons suggested that many transcripts
related to metabolism, transcripts encoding mitochondrial pro-
teins, transcripts related to lipid, protein and vesicle-mediated
transport and transcripts related to kinase/phosphatase signaling
are more highly expressed in SNpc neurons, whereas transcripts
implicated in axon guidance or in neuropeptide signaling were
mainly enriched in VTA neurons (Chung et al., 2005; Greene
et al., 2005). Grimm et al. found that many genes encoding
for proteins involved in synaptic plasticity, cell survival (neuro-
protection, detoxification) or axonal pathfinding and neuronal
migration are more highly expressed in the VTA (Grimm et al.,
2004). Several of the differentially expressed gene candidates were
confirmed by all three microarray studies and a small selection
of interesting candidates was discussed elsewhere (Greene, 2006).
However, the overall overlap observed between these three studies
is limited which, at least in part, might be due to the facts that
two studies were carried out in rats and one study in mice, and
that different microarray chips with comparably small numbers
of probe sets were used for sample analysis. Consequently, even
with these expression data at hand, the identification of specific
key molecular pathways that clearly mediate the selective DA
neuron vulnerability in PD has remained challenging. Chung
et al. investigated two VTA DA neuron-enriched transcripts in
more detail: G-substrate and Rab3b (Chung et al., 2007, 2009).
G-substrate is an endogenous inhibitor of Serine/Threonine pro-
tein phosphatases, while Rab3b is an isoform belonging to the
Rab3 GTPase protein family that is enriched in synaptic vesicles in
neurons and involved in synaptic vesicle trafficking. Interestingly,
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the virus-mediated overexpression of either candidate in SNpc
DA neurons in rats protected these neurons from 6-OHDA-
mediated neurodegeneration. However, protein overexpression in
a different animal model that more closely resembles the slow,
progressive DA neuron loss in PD, such as the subacute MPTP-
induced mouse model, was not pursued. Moreover, convincing
data indicating that boosting G-substrate or Rab3b function may
attenuate SNpc DA neuron degeneration in PD are lacking thus
far. Additionally, the development of small molecules that are
able to specifically activate Rab3b or G-substrate in the SNpc
might be hampered by the expression of both proteins in brain
regions other than the midbrain and their apparent involvement
in various different signaling pathways whose manipulation could
potentially interfere with normal brain function (Endo et al.,
2009; Tsetsenis et al., 2011).
Surprisingly, the elucidation of the molecular determinants
of the differential vulnerability of SNpc and VTA DA neurons
in PD has received little attention since. One study investigated
the transcriptional changes in SNpc and VTA DA neurons in
mice after the injection of saline or 4 mg MPTP/kg/day for two
days or 10 days (Phani et al., 2010). This injection schedule is
unconventional and has not been described in the literature. The
authors observed a 30% loss of SNpc DA neurons in MPTP-
treated animals after two days and a 70% loss after 10 days. In
the VTA, only 10% of DA neurons degenerated and this loss did
not progress over time. Mice were sacrificed seven days after the
final injection. Following the isolation of DA neurons by LCM
and RNA purification, expression analysis was carried out using
microarrays. The conclusions of this investigation remained very
general, stating that a number of genes were up-regulated in the
VTA as compared to the SNpc after exposure to MPTP. Almost
no overlap existed between the genes up-regulated before and
after MPTP treatment, and only very few genes were consistently
up-regulated at two days and at 10 days after MPTP treatment,
which is somewhat in contrast to the fact that no progressive
VTA DA neuron loss was observed. These results suggest that the
expression signature of VTA DA neurons may be very variable
depending on the respective experimental conditions. However,
independent confirmation of this finding using the same or a
similar animal model is desired. In a follow-up study, Phani
et al. suggested that the exogenous addition of the peptide grem-
lin, whose mRNA levels were elevated in the VTA DA neurons
after MPTP treatment of mice, protects SNpc DA neurons from
MPP+-induced degeneration, possibly via vascular endothelial
growth factor receptor 2 (Phani et al., 2013). Data from additional
animal models or human data were not presented, and due to
its peptide nature, the delivery of gremlin to the SNpc could
be problematic for the development of a therapy. Another study
laser-captured DA neurons from rats infused with rotenone for 28
days or from mice acutely treated with MPTP and investigated the
levels of a set of transcripts related to energy metabolism using
quantitative real-time PCR (Greene et al., 2010). SNpc DA neu-
rons demonstrated higher baseline levels and more pronounced
changes in the levels of these transcripts than VTA DA neurons.
These findings are in agreement with those from Chung et al.
and are interesting particularly in light of the predicted higher
metabolic demand of SNpc DA neurons which is discussed below.
The mechanisms underlying these DA neuron subtype-specific
observations remain to be elucidated.
Future studies addressing the gene expression differences
between SNpc and VTA DA neurons would be of great interest,
in particular if next-generation sequencing is used as an unbiased
method to unequivocally identify and more accurately quantify
the entirety of all transcripts that are expressed at different stages
of DA neuron degeneration. In addition, the preferred applica-
tion of the more sophisticated bacTRAP methodology over LCM
would most likely result in a significant refinement of the available
data sets that describe the gene expression profiles of midbrain DA
neurons, as bacTRAP focuses on the specific analysis of translated
messages and does not include translationally silent RNAs (Doyle
et al., 2008; Heiman et al., 2008).
G-PROTEIN-ACTIVATED INWARDLY RECTIFYING
POTASSIUM CHANNEL 2 (GIRK2)
GIRK2 has long been considered a protein whose expression pat-
tern may potentially correlate with the differential vulnerability
of subgroups of midbrain DA neurons. It represents one family
member of a group of ion channels and is involved in the reg-
ulation of neuronal activity (Kobayashi and Ikeda, 2006). Weaver
mice carry a homozygous missense mutation in the gene encoding
for GIRK2 (Patil et al., 1995) which leads to the progressive loss of
SNpc DA neurons that starts after postnatal day 7 and reaches a
69% loss on postnatal day 90 (Triarhou et al., 1988; Verney et al.,
1995). Ventral SNpc DA neurons are most severely affected by the
degeneration (Graybiel et al., 1990). In contrast, the loss of DA
neurons in the VTA is delayed and less severe than in the SNpc
(Triarhou et al., 1988; Graybiel et al., 1990; Martí et al., 2000,
2007). Although the conclusions presented in these studies are
convincing, it is noteworthy that these investigations did not apply
state-of-the-art stereological methods to determine the number
of surviving DA neurons. Therefore, the presented percentages
and cell numbers may slightly deviate from the actual values.
Also, caution is required when interpreting these findings in the
context of PD, as degeneration in weaver mice starts before the
complete maturation of SNpc DA neurons, which may introduce
a developmental component that is not present in PD.
Initial in-situ hybridization and immunohistochemistry stud-
ies in adult control mice showed that most SNpc DA neurons
and lateral VTA DA neurons express Girk2/GIRK2, while the
majority of medial VTA DA neurons seemed to lack detectable
Girk2/GIRK2 levels (Schein et al., 1998). Schein et al. also sug-
gested that the fraction of VTA DA neurons that areGirk2/GIRK2-
positive express lower levels than Girk2/GIRK2-positive SNpc DA
neurons (Schein et al., 1998). These findings implied an overall
enrichment of Girk2/GIRK2 in the SNpc as compared to the VTA,
although the absence or presence of Girk2/GIRK2 could not serve
as a qualitative marker to clearly distinguish between these two
DA nuclei.
Several subsequent studies in humans, mice and rats then
suggested that the expression of GIRK2 distinguishes between
the DA neurons in the dorsal and ventral tier of the SNpc, as
GIRK2 was detected particularly in ventral tier SNpc DA neu-
rons (Mendez et al., 2005; Thompson et al., 2005; Björklund
and Dunnett, 2007). These data gave rise to speculations that
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GIRK2 may not only differentiate between SNpc and VTA DA
neurons, but it may also serve as a molecular marker for ventral
SNpc DA neurons which show the highest vulnerability in PD.
However, a functional explanation for this observation was not
provided.
In an extensive immunohistochemistry study in tissue samples
from five human brain donors and six wild-type mice, Reyes et al.
recently revisited the expression of GIRK2 protein in midbrain DA
neurons (Reyes et al., 2012). This study revealed that some level of
GIRK2 is expressed in almost all TH-positive neurons in the SNpc
and the VTA in mice and in almost all neuromelanin-positive
neurons in human midbrain. In both species, most GIRK2-
positive SNpc DA neurons showed strong expression of GIRK2,
while few SNpc DA neurons were characterized by weak GIRK2
expression. Importantly, no significant difference was observed
between the GIRK2 expression pattern in dorsal and ventral tier
SNpc DA neurons. In both tiers, the vast majority of SNpc DA
neurons were positive for GIRK2, and similarly high numbers
of these neurons showed high GIRK2 expression levels. These
findings suggest that GIRK2 expression does not distinguish
between dorsal and ventral tier SNpc DA neurons. Most VTA TH-
positive neurons in mice and humans also expressed some level
of GIRK2. Therefore, the qualitative assessment of GIRK2 expres-
sion cannot serve as a tool to discriminate between SNpc and VTA
DA neurons. However, strong GIRK2 expression was detected
in about half of the VTA DA neurons, which represents a large
fraction of VTA DA neurons but is a considerably smaller number
than that of DA neurons with high GIRK2 levels in the SNpc.
Consistent with these data, Chung et al. recently reported that,
overall, Girk2 mRNA levels are higher in SNpc DA neurons than
in VTA DA neurons (Chung et al., 2005). This was demonstrated
in adult wild-type mice using LCM of DA neurons followed by
quantitative real-time PCR.
Strikingly, another recent immunohistochemistry study in
mice further confirmed that GIRK2 is expressed in almost all
SNpc TH-positive neurons in both ventral and dorsal tiers, as
well as the majority of VTA TH-positive neurons (Fu et al., 2012).
Similar results were obtained in an immunohistochemistry study
in rats (Eulitz et al., 2007). Fu et al. did not confirm that more
SNpc DA neurons express high levels of GIRK2 than VTA DA
neurons (Fu et al., 2012).
Taken together, these results indicate that GIRK2 is unlikely
to be a marker to distinguish between dorsal and ventral tier
SNpc DA neurons, and that the GIRK2 expression pattern does
not correlate with the differential vulnerability of these two SNpc
DA neuron subgroups in PD. It is unclear at this point if GIRK2
contributes to the selective vulnerability of SNpc and VTA DA
neurons. It appears that a larger fraction of SNpc DA neurons than
VTA DA neurons express high GIRK2 levels, which is consistent
with the overall enrichment of Girk2 transcript in the SNpc
as compared to the VTA. However, the observations that the
majority of VTA DA neurons do express some GIRK2 and that
a considerable percentage of VTA DA neurons contain GIRK2
levels as high as most SNpc DA neurons complicate matters and
weaken the potential relevance of GIRK2 as a therapeutic target, as
these findings do not unequivocally correlate with the differential
susceptibility of SNpc and VTA DA neurons in PD.
CALBINDIN
Calbindin is a calcium-binding protein that is widely expressed
in many brain areas and involved in the regulation of intracel-
lular calcium levels (Liu and Graybiel, 1992). Similar to GIRK2,
many studies have suggested calbindin as a marker to distinguish
between midbrain DA neurons with different susceptibility to
degeneration in PD. Gene expression profiling studies in rats
and mice applying LCM in combination with microarray analysis
demonstrated that calbindin transcripts are enriched in VTA DA
neurons as compared to SNpc DA neurons (Chung et al., 2005;
Greene et al., 2005). Immunostaining in mice and rats revealed
that TH-positive cells in both SNpc and VTA express calbindin.
However, the number of TH-positive VTA neurons that co-
express calbindin is higher than that of TH-positive SNpc neurons
(Liang et al., 1996; Björklund and Dunnett, 2007). Within the
SNpc, TH-positive, calbindin-expressing neurons were mainly
found in the dorsal tier. A similar calbindin expression pattern
was observed in human midbrain (Mendez et al., 2005).
In their recent immunohistochemistry study in tissue sam-
ples derived from five human controls and six wild-type mice,
Reyes et al. confirmed many of the previously reported data
regarding the expression of calbindin in midbrain DA neu-
rons (Reyes et al., 2012). In the mouse and human SNpc,
fewer TH- or neuromelanin-positive neurons contained cal-
bindin than in the VTA. These neurons were mainly localized
in the medial and lateral SNpc, and a very small number of
calbindin-positive DA neurons were also detected in the dor-
sal SNpc. However, calbindin-positive neurons were completely
absent from the ventral tier of the SNpc. A much larger frac-
tion of TH- or neuromelanin-positive VTA neurons in mice
and humans, respectively, contained calbindin. These findings
correlate with the overall enrichment of calbindin transcripts in
VTA DA neurons over SNpc DA neurons that was reported in
the LCM/microarray expression studies discussed above (Chung
et al., 2005; Greene et al., 2005). Nevertheless, the expression pat-
tern of calbindin does not accurately reflect the different degrees
of DA neuron vulnerability. Many but not all VTA DA neurons
express calbindin, and some SNpc DA neurons express calbindin
as well, such that calbindin expression cannot serve as a qualitative
marker to clearly distinguish between SNpc and VTA. Moreover,
calbindin is indeed absent from ventral tier SNpc DA neurons,
but not all dorsal tier SNpc DA neurons contain calbindin, which
raises the question how closely the expression pattern of calbindin
correlates with the differential vulnerability of dorsal and ventral
tier SNpc DA neurons.
Fu et al. also revisited the expression of calbindin in mouse
midbrain using immunohistochemistry and confirmed that no
SNpc DA neurons in the ventral tier express calbindin (Fu et al.,
2012). In the dorsal tier, a signal for calbindin was detected
in fewer than 2% of SNpc DA neurons, suggesting that some
difference exists between the ventral and dorsal tiers of the SNpc.
However, many dorsal tier SNpc DA neurons do not follow this
expression pattern as they are calbindin-negative, underscoring
the view that calbindin does not represent a suitable marker for
different degrees of DA neuron vulnerability. Also in agreement
with previously published data, it was demonstrated that some
TH-positive neurons outside the dorsal tier of the SNpc express
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calbindin, particularly in the medial and lateral SNpc, but the
number of TH- and calbindin-positive neurons in these SNpc
regions was lower than that in the VTA.
Several years ago, it was demonstrated that the presence or
absence of calbindin in SNpc and VTA DA neurons correlates with
distinct electrophysiological features of these DA neuron sub-
groups that are mediated by hyperpolarization-activated, cyclic
nucleotide-regulated cation (HCN) channels (Neuhoff et al.,
2002). Interestingly, another electrophysiological study now iden-
tified a novel function for calbindin in midbrain DA neurons
expressing this protein (Pan and Ryan, 2012). Using rat midbrain
DA neuronal cultures, an inverse correlation was demonstrated
between the expression level of calbindin and the probability of
vesicle exocytosis, suggesting that calbindin is involved in the
control of dopamine release. Based on these results, it appears
that calbindin-negative SNpc DA neurons are characterized by a
higher dopamine release probability than most VTA DA neurons
which are calbindin-positive. However, this study did not address
the heterogeneous expression of calbindin that is observed among
SNpc DA neurons and also among VTA DA neurons. No experi-
ments were carried out to investigate if and how this mechanism
can be linked to the differential vulnerability of DA neurons in
PD. Early investigations indicated that calbindin does not directly
mediate protection, as the same subgroups of DA neurons were
spared from degeneration in MPTP-treated calbindin knockout
mice and in their wild-type littermates (Airaksinen et al., 1997).
However, some caution is recommended when interpreting these
data, as this study did not yet apply the stereological methods that
are currently considered state-of-the-art to accurately determine
neuronal numbers. In consideration of the available data, and
based on the complex expression pattern of calbindin in SNpc and
VTA DA neurons, many questions remain regarding the suitability
of calbindin as a marker for DA neurons with increased resistance
to degeneration in PD and the potential role of calbindin in
mediating differential DA vulnerability.
RECEPTORS AND TRANSPORTERS
DA neurons express a variety of cell surface receptors and
transporters that may serve as potential binding or entry sites
for neurotoxic substances. Providing proof of concept for this
hypothesis, it is well established that MPP+ is taken up specifically
by DA neurons via DAT, resulting in mitochondrial damage and
ultimately DA neurodegeneration (Dauer and Przedborski, 2003).
In the context of differential DA vulnerability, it may be feasible
to speculate that in particular the most vulnerable DA neurons
express a unique set of transporters and/or receptors that facilitate
the uptake of or transmit extracellular signals initiated by PD-
related neurotoxins. A number of studies have focused on the
expression pattern of various receptors in the midbrain DA system
over the years. In one of the most recent investigations, Reyes
et al. applied immunohistochemistry and co-staining for TH to
analyze the expression patterns of the five dopamine receptors
and DAT in post-mortem human midbrain tissue in great detail
(Reyes et al., 2013a). The dopamine receptors D1, D2, D3 and
D5 were detected in most SNpc and VTA DA neurons, although
slightly fewer VTA DA neurons were positive for D1 and D2,
respectively, than SNpc DA neurons. Notably, considerably more
SNpc DA neurons than VTA DA neurons showed high expression
levels of the D1 or D2 receptor. Similarly, while most midbrain
DA neurons expressed DAT, significantly more SNpc DA neurons
than VTA DA neurons expressed high levels of DAT. Reyes et al.
also investigated the levels of glycosylated DAT which is the
mature, highly functional version of this transporter (Li et al.,
2004). While more than 90% of the analyzed SNpc DA neurons
and more than 80% of the analyzed VTA DA neurons expressed
some level of glycosylated DAT, high levels of glycosylated DAT
were found, in particular, in a fraction of DA neurons located in
the most vulnerable ventral tier of the SNpc. This is in agreement
with the findings of another immunohistochemistry study in rats
and human midbrain (Afonso-Oramas et al., 2009). However,
ventral tier SNpc DA neurons did not show uniform expression
levels of glycosylated DAT, and fewer than 20% of these neurons
were characterized by high levels. If the reported differences in the
expression levels of some dopamine receptors and DAT indeed
contribute to the differential DA vulnerability, the underlying
mechanism remains to be determined. Importantly, D1, D2 and
glycosylated DAT are present in almost all midbrain DA neurons,
only at slightly different levels, and it is unclear how these rather
small expression differences would be able to account for the
varying degrees of vulnerability observed between SNpc and VTA
DA neurons or between DA neurons in the dorsal and ventral tiers
of the SNpc.
In this context, it is noteworthy to mention that SNpc and VTA
DA neurons receive input from a considerable number of different
brain areas. In an elegant study that was carried out in mice, the
Cre/LoxP system was combined with rabies virus-based transsy-
naptic retrograde tracing to generate a comprehensive list of the
brain areas that provide monosynaptic input to SNpc or VTA DA
neurons or both (Watabe-Uchida et al., 2012). Not surprisingly,
it was demonstrated that each group of midbrain DA neurons
is innervated by an overlapping, yet distinct set of brain areas.
These data clearly show that SNpc and VTA DA neurons are wired
differently in the brain and that each of these two DA neuron
groups receives and integrates a distinct set of signals. Although
not all of the findings from mice may carry over to the human
brain, it can be speculated that SNpc DA neurons may receive
toxic inputs that do not reach the VTA, or VTA DA neurons may
receive protective signals that do not reach the SNpc. Together,
the slightly different connectivity of SNpc and VTA DA neurons
within the brain and small differences in the expression levels of
specific receptors at the cell surface of SNpc and VTA DA neurons
may contribute to the differential vulnerability of these neurons
observed in PD. This hypothesis is also interesting in light of a
recent investigation in mice which showed that the introduction
of preformed fibrils of alpha-synuclein to a particular brain region
led to the progressive propagation of Lewy Body/Lewy neurite
pathology in other brain regions based on the connectivity of
neurons and cell-to-cell transmission (Luk et al., 2012). After
the stereotaxic injection of preformed fibrils consisting of recom-
binant mouse alpha-synuclein into the dorsal striatum, severe
alpha-synuclein pathology was observed in the SNpc TH-positive
neurons but not in the VTA TH-positive neurons. This is consis-
tent with the fact that the dorsal striatum is heavily innervated by
the SNpc DA neurons while VTA DA neurons send significantly
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fewer projections to this area, providing an example of how
differences in the neuronal connectivity of midbrain DA neurons
can lead to the selective damage of distinct DA neuron groups.
Importantly, the propagation of alpha-synuclein pathology is a
process that very likely also occurs in the human brain, which
has been demonstrated by the identification of alpha-synuclein-
positive inclusions in DA neuron grafts years after transplantation
into the striatum of patients with PD (Kordower et al., 2008a,b; Li
et al., 2008).
ELECTROPHYSIOLOGICAL DETERMINANTS
It has long been suggested that SNpc DA neurons are charac-
terized by autonomous pacemaking which is driven by calcium
channels (Nedergaard et al., 1993; Mercuri et al., 1994). However,
one of the major findings regarding the differential vulnerabil-
ity of SNpc and VTA DA neurons came from a well-designed
electrophysiological study in mice which demonstrated that only
adult SNpc DA neurons rely on L-type Cav1.3 calcium channels
for pacemaking, whereas juvenile SNpc DA neurons and VTA DA
neurons rely on voltage-dependent sodium channels (Chan et al.,
2007). This reliance of adult SNpc DA neurons on calcium for
pacemaking seems to result in increased cytosolic calcium levels
and elevated levels of oxidative stress, which could explain the
higher vulnerability of SNpc DA neurons to damaging insults
and degeneration in PD (Guzman et al., 2010). Another study
in cultured murine midbrain DA neurons demonstrated that
the reliance of SNpc DA neurons on calcium for pacemaking
facilitates the L-DOPA-induced increase of dopamine to cytotoxic
levels (Mosharov et al., 2009). This L-DOPA-induced increase
of intracellular dopamine levels was not observed in VTA DA
neurons, which provided further insight into physiological dif-
ferences between SNpc and VTA DA neurons. However, the
molecular basis of these observations remains largely unclear. It
is unknown which factors and pathways force maturing SNpc
DA neurons into using calcium channels for pacemaking, and
why and how VTA neurons escape the switch from sodium to
calcium channels. Moreover, it is not understood which endoge-
nous mechanisms SNpc DA neurons possess to counterbalance
the continuous, calcium-related oxidative stress in order to sur-
vive under control conditions. Clearly, the identification of these
SNpc-specific pro-survival mechanisms has the potential to lead
to the development of exciting novel therapeutic targets for the
treatment of PD.
Electrophysiological differences between SNpc and VTA DA
neurons were also revealed in a study focusing on the role of
Kir6.2 and SUR1 subunit-containing ATP-sensitive potassium (K-
ATP) channels in DA neurodegeneration in mice (Liss et al.,
2005). In mouse brain slice cultures treated with the mito-
chondrial neurotoxins MPP+ or rotenone, spontaneous electrical
activity was abolished exclusively in SNpc DA neurons, while
VTA DA neurons remained unaffected. This was explained by
the selective activation of K-ATP channels in SNpc DA neurons.
Since K-ATP channels in SNpc and VTA DA neurons consist of
the same subunits, the molecular composition of the channels did
not account for these findings. However, the study suggested that
the different responses of SNpc and VTA DA neurons may be due
to different degrees of mitochondrial uncoupling, which controls
the activation of K-ATP channels, most likely via different lev-
els of reactive oxygen species (ROS). These findings are inter-
esting and warrant further investigation and confirmation of
these mechanisms in vivo. Interestingly, using LCM and mRNA
quantification, a subsequent investigation provided evidence for
the increased expression of the K-ATP channel subunit SUR1 in
SNpc DA neurons from patients with PD as compared to controls
(Schiemann et al., 2012). Moreover, based on intra-operative
measurements in PD patients, it was suggested that K-ATP
channel-dependent burst firing is elevated in surviving DA neu-
rons in the SNpc. Although the latter findings in particular need
to be interpreted with caution due to the obvious lack of suitable
control measurements, these data may further argue for a role
of K-ATP channels in the degeneration specifically of SNpc DA
neurons.
Bishop et al. established a preliminary link between PD caused
by PINK1 mutations, calcium, and the different electrophysiolog-
ical properties of SNpc and VTA DA neurons (Bishop et al., 2010).
A comparison of brain slices from wild-type and Pink1 knockout
mice revealed that PINK1 deficiency in SNpc DA neurons is
associated with irregular firing patterns due to the reduced activa-
tion of small-conductance calcium-activated potassium channels
which was caused by impaired calcium release from the mito-
chondria and the endoplasmic reticulum. The authors speculated
that the observed changes in the SNpc DA neuron firing pattern
may eventually contribute to the increased calcium burden of
these neurons and further elevate cellular stress. However, direct
evidence for this particular hypothesis was not provided in the
study. In contrast, VTA DA neurons did not change their firing
patterns as a result of PINK1 deficiency, although the activity
of small-conductance calcium-activated potassium channels was
similarly decreased as in SNpc DA neurons. This was explained
by the fact that SK3, the small-conductance calcium-activated
potassium channel member whose mRNA is most abundant in
midbrain DA neurons, is expressed at lower levels in VTA than
in SNpc DA neurons and does not control certain aspects of
pacemaking in the VTA as it does in the SNpc (Wolfart et al.,
2001). Taken together, these findings are certainly of interest and
demonstrate that the different molecular profiles of SNpc and
VTA DA neurons may have significant consequences for the phys-
iologic properties of these neurons and their differential response
to PD-related changes. However, some of the conclusions of this
study are still preliminary and require further investigation to
identify all of the molecular components involved in mediating
the differential response of SNpc and VTA DA neurons. It would
also be of interest to compare the effects of PINK1 deficiency
with PINK1 overexpression or to investigate the consequences
that other PD-related mutations may have on DA neuron elec-
trophysiology.
DEVELOPMENTAL TRANSCRIPTION FACTORS
The developmental formation of the midbrain, the differentiation
of DA progenitor cells, and the induction of DA neuron mark-
ers are complex processes that require the spatial and temporal
expression of specific sets of transcription factors (reviewed in
(Smidt et al., 2003)). It has been demonstrated in mice that
a close correlation exists between the developmental position
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of different DA progenitors, the expression pattern of specific
protein markers that are typically present in subsets of these cells,
and the vulnerability of the corresponding adult DA neurons in
PD (Smits et al., 2013). Interestingly, some of the transcription
factors expressed during neurogenesis remain expressed in the DA
neurons during adulthood, and based on their expression patterns
in SNpc and VTA DA neurons, a role in mediating the differential
vulnerability of midbrain DA neurons has been hypothesized for
these proteins.
Pituitary homeobox 3 (PITX3) is a transcription factor that
is crucial for the development of SNpc DA neurons. Aphakia
mice carry a homozygous null mutation in the Pitx3 locus which
results in the lack of PITX3 expression in the midbrain (Semina
et al., 2000; van den Munckhof et al., 2003). While midbrain
DA neurons appear normal in aphakia mice until embryonal day
E12.5, PITX3 deficiency then interferes with the further devel-
opment and the maintainance of SNpc DA neurons, resulting in
severe DA neuron loss (Hwang et al., 2003; Nunes et al., 2003;
van den Munckhof et al., 2003). In contrast, VTA DA neurons
were observed to first develop normally. However, using unbiased
stereology to estimate the number of TH-positive neurons, signif-
icant loss of VTA DA neurons was found in adult aphakia mice at
the age of ∼3 months (van den Munckhof et al., 2003; Luk et al.,
2013). Although this loss was less severe than in the SNpc, these
data suggest that PITX3 may also play a role for the long-term
survival of VTA DA neurons.
For wild-type mice, it was reported that PITX3 is mainly
expressed in the DA neurons in the ventral SNpc and in about
50% of VTA DA neurons without demonstrating non-DA neuron
expression in the midbrain (van den Munckhof et al., 2003). The
DA neurons in the dorsal SNpc were mainly PITX3-negative,
which is consistent with the finding that in aphakia mice, some
TH-positive cells were spared in the dorsal tier of the SNpc
as these neurons may not require PITX3 to survive (van den
Munckhof et al., 2003). The expression pattern of PITX3 in
the midbrain has been investigated in several studies since and
the reported results are controversial. In a study in three- to
four-week-old rats, co-immunofluorescence staining for TH and
PITX3 revealed that almost all SNpc and VTA DA neurons express
PITX3 (Korotkova et al., 2005). A qualitative difference in PITX3
expression between the dorsal and ventral tiers of the SNpc
was not observed. Two additional, very recent studies focused
on the expression pattern of PITX3 in the midbrain. Luk et al.
confirmed the localization of PITX3-positive SNpc DA neurons
predominantly to the ventral tier and of PITX3-negative SNpc DA
neurons to the dorsal tier in wild-type mice (Luk et al., 2013).
It was reported that, in the VTA, many TH-positive neurons
contained PITX3, and PITX3-positive and PITX3-negative DA
neurons appeared intermixed with each other. However, it is
not entirely clear from this study how many VTA TH-positive
neurons expressed PITX3. Furthermore, Luk et al. compared the
expression pattern of PITX3 with that of calbindin and found
that the majority of SNpc DA neurons expressed either PITX3
or calbindin, but not both. In agreement with this observation,
it was demonstrated in aphakia mice that the PITX3-negative DA
neurons in the dorsal tier of the SNpc which escape degeneration
are positive for calbindin. In contrast, the expression of calbindin
in PITX3-negative VTA DA neurons was not sufficient to prevent
degeneration of all of these neurons, which could point to a poten-
tial SNpc-specific survival mechanism of DA neurons expressing
calbindin while lacking PITX3. Unfortunately, these findings are
currently limited to the description of expression patterns, and a
causal relationship between the absence of PITX3, the presence
of calbindin and increased resistance to degeneration was not
provided. Importantly, the potential function of PITX3 in adult
midbrain DA neurons and its relevance for DA neuron vulnera-
bility remains unclear. Immunostaining of brain slices obtained
from wild-type mice after treatment with MPTP suggested that
PITX3-expressing DA neurons are more vulnerable to the effects
of this neurotoxin than PITX3-negative SNpc neurons. While it is
well known that ventral SNpc DA neurons are more vulnerable to
degeneration than dorsal SNpc DA neurons, convincing evidence
for a direct link between this observation and the expression of
PITX3 is missing. Interestingly, heterozygous aphakia mice with
reduced PITX3 expression showed increased DA neuron loss in
the SNpc after MPTP treatment. These results would suggest
that PITX3 is neuroprotective, which is in contrast to the higher
vulnerability of PITX3-positive SNpc neurons to MPTP than
PITX3-negative neurons, and needs to be investigated in more
detail to confirm that these observations are indeed due to the
presence or absence of PITX3. Moreover, in these studies, MPTP
was administered to mice at postnatal day 35, which represents
a rather young mouse age at which DA neuron maturation may
not entirely be completed, and thus the study results might be
influenced by the contribution of developmental factors.
Another immunohistochemistry study in mouse and human
tissue samples confirmed the DA neuron-specific expression of
PITX3 in the midbrain (Reyes et al., 2013b). However, in humans,
PITX3 was found to be expressed in more than 90% of DA
neurons in both SNpc and VTA, suggesting that almost all DA
neurons in both nuclei express some level of PITX3. In mice,
more than 90% of SNpc DA neurons and about 80% of VTA DA
neurons expressed PITX3, presenting a similar situation as in the
human midbrain. The authors did not observe differences in the
PITX3 expression pattern between the dorsal and ventral tiers of
the SNpc. Interestingly, an analysis of publicly available human
microarray data implied that PITX3 transcripts are enriched in
the SNpc as compared to the VTA, possibly pointing to SNpc DA
neurons expressing higher PITX3 levels than VTA DA neurons.
Taken together, various studies have described different
expression patterns of PITX3 in the midbrain DA neurons even
for the same species. The reason for these discrepancies is
unknown, although it is possible that different degrees of sensi-
tivity were reached with the different immunostaining protocols
that were applied, resulting in the detection of low PITX3 levels in
a subset of DA neurons in one study, while another study might
have been less sensitive, leaving these DA neurons unlabeled.
Therefore, it currently remains unclear if PITX3 can serve as
a marker for subsets of midbrain DA neurons with different
susceptibility to degeneration. Moreover, the data regarding the
enrichment of PITX3 mRNA in the SNpc as compared to the VTA
need to be supported by additional studies, as only a very limited
number of subjects was investigated by Reyes et al. Furthermore,
future investigations should focus on the function of PITX3 in
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adult DA neurons to identify the molecular pathways in which
PITX3 is involved. These data may provide clues regarding the
potential role of PITX3 in regulating the vulnerability of DA
neurons to degeneration.
The nuclear receptor NURR1 is another transcription factor
that is involved in the specification of midbrain DA neurons.
Nurr1 mRNA is detectable in the mouse midbrain as early as at
embryonic day 10.5, and only after this time point, the expression
of mRNAs encoding for DA neuron markers such as TH is
induced (Zetterström et al., 1997). In Nurr1 knockout mice, the
final differentiation of DA precursors to neurons is inhibited and
SNpc and VTA DA neurons are not generated in the midbrain
(Zetterström et al., 1997; Castillo et al., 1998; Saucedo-Cardenas
et al., 1998). Adult wild-type mice express NURR1 in almost
all TH-positive neurons in the SNpc and the VTA, and several
studies have demonstrated that NURR1 supports the mainte-
nance and normal function of these neurons (Bäckman et al.,
1999; Kadkhodaei et al., 2009, 2013). Differential expression of
NURR1 in subgroups of midbrain DA neurons has not been
observed, making it unlikely that NURR1 plays a role in selective
DA vulnerability. Similarly, the homeobox proteins engrailed-1
and engrailed-2 are expressed in SNpc and VTA DA neurons
in mice from early developmental stages into adulthood (Simon
et al., 2001). Engrailed-1 seems to be expressed at high levels in all
midbrain DA neurons, whereas engrailed-2 is mostly expressed at
lower levels and high expression is found only in a subset of DA
neurons. In particular, engrailed-1 is of paramount importance
for the development of SNpc and VTA DA neurons, and also plays
a role in their postnatal maintenance (Simon et al., 2001; Albéri
et al., 2004; Sgadò et al., 2006; Sonnier et al., 2007; Nordström
et al., 2014). However, based on the published data, the expression
pattern of engrailed-1 does not differ between subgroups of DA
neurons. Although it has been reported that the expression levels
of engrailed-2 are not uniform among midbrain DA neurons in
adult mice (Simon et al., 2001), a correlation between engrailed-
2 levels and the differential susceptibility of DA neurons has not
been carried out.
The neurogenesis of DA neurons in the mouse midbrain is
partially controlled by the homeobox protein OTX2 (Omodei
et al., 2008). Although OTX2 is expressed in all midbrain DA
progenitors, this transcription factor appears to be of varying
importance for the development of different subgroups of DA
neurons (Di Giovannantonio et al., 2013). Based on data obtained
in conditional Otx2 knockout and OTX2 overexpressing mice, it
was suggested that OTX2 is of paramount importance for the
generation of only a specific subgroup of VTA DA neurons (Di
Giovannantonio et al., 2013). In adult mice, LCM of SNpc and
VTA DA neurons combined with microarray expression analysis
revealed that Otx2 is about 6-fold enriched in the VTA as com-
pared to the SNpc (Chung et al., 2005). This enrichment in the
VTA was confirmed by the quantitative real-time PCR analysis of
RNA samples collected from mouse or human SNpc and VTA DA
neurons, respectively (Chung et al., 2010). Co-immunostaining of
adult mouse midbrain for TH and OTX2 revealed OTX2 expres-
sion in many VTA DA neurons, but not in SNpc DA neurons
(Chung et al., 2010; Di Salvio et al., 2010b). It was demonstrated
that the DA neurons in the ventral and central VTA express OTX2.
However, OTX2 expression was not exclusively restricted to DA
neurons as some non-DA neurons in the VTA were also positive
for OTX2 (Di Salvio et al., 2010b). Consistent with the data
discussed above, it was observed that OTX2-expressing neurons
are often positive for calbindin but only rarely co-express GIRK2.
Moreover, the manipulation of OTX2 levels in midbrain DA
neurons demonstrated that the depletion of OTX2 in the VTA
leads to the expression of GIRK2, increased levels of the functional
glycosylated form of DAT and increased neuronal vulnerability
to MPTP, which is consistent with a potential neuroprotective
role of OTX2 in VTA DA neurons (Di Salvio et al., 2010a). How
OTX2 is able to control the expression of glycoslylated DAT and
GIRK2 and the molecular pathway connecting altered DA neu-
ron vulnerability with the expression of these proteins currently
remains speculation. A neuroprotective role was also suggested
by a different study in which OTX2 was either overexpressed
or knocked down in primary mouse midbrain cultures using
lentivirus technology (Chung et al., 2010). After MPP+ treatment,
OTX2 overexpression resulted in an increased number of TH-
positive neurons as compared to control cultures, whereas OTX2
knockdown led to a reduced number of TH-positive neurons,
further indicating that OTX2 may decrease the susceptibility of
DA neurons to toxin-induced degeneration.
Surprisingly, recent data presented by Reyes et al. imply that
the potentially protective role of OTX2 in VTA DA neurons is
not conserved between mice and humans (Reyes et al., 2013b).
In agreement with previous analyses of adult mouse midbrain
tissue, OTX2 immunoreactivity was detected in VTA DA neurons
and not in SNpc DA neurons. These findings were consistent in
tissue samples obtained from mice at different ages, ranging from
four weeks to two years. In contrast, human SNpc and VTA DA
neurons did not show any OTX2 expression either in middle-
aged (58 ± 16 years old) or in aged control subjects (85 ± 3
years old) although a signal for OTX2 was detected in other brain
regions. An analysis of OTX2 mRNA levels in SNpc and VTA DA
neurons in a 24-year-old and a 39-year-old individual suggested
that OTX2 expression is detectable at some point but severely
declines with age. The latter data may also explain why Chung
et al. were able to detect OTX2 mRNA in laser-captured human
VTA DA neurons (Chung et al., 2010). The findings by Reyes et al.
would suggest that OTX2 does not play a neuroprotective role in
aged human VTA DA neurons. However, these data need to be
considered preliminary as only a very limited number of subjects
were included in this analysis.
DELETED IN COLORECTAL CANCER
Besides transcription factors that play a role in the developing
midbrain and that have been discussed in the previous section,
another developmentally expressed protein has been investigated
regarding its differential expression among adult midbrain DA
neurons. Deleted in colorectal cancer (DCC), the receptor for
the axon guidance molecule netrin, is located at the cell sur-
face and highly expressed in the developing midbrain and at
lower levels in the adult midbrain in rodents (Livesey and Hunt,
1997; Stein et al., 2001). The interaction between netrin and the
DCC receptor is crucial for the guidance of SNpc and VTA DA
axons to their respective striatal target regions (Li et al., 2014).
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Interestingly, in the adult rodent midbrain, co-immunostaining
experiments revealed that DCC expression is largely restricted to
TH-positive neurons, and most DCC-positive DA neurons were
located in the ventral part of the SNpc (Osborne et al., 2005).
Only few VTA DA neurons expressed DCC, and, for the most
part, DCC-positive DA neurons in the SNpc and the VTA were
negative for calbindin and vice versa. These data suggest that
DCC may be useful as a marker for the population of SNpc DA
neurons that are most vulnerable to degeneration. Reyes et al.
investigated the DCC expression in human and mouse midbrain
and observed that, in humans, more than 90% of DA neurons
in the dorsal and ventral SNpc and in the VTA expressed this
receptor. However, an overall enrichment of DCC mRNA in the
SNpc as compared to the VTA was found, implying that DCC
is expressed by almost all DA neurons, but the average DCC
level may be higher in the DA neurons in the SNpc than in the
VTA. In mouse midbrain, all ventral SNpc DA neurons expressed
DCC, but only ∼85% of dorsal SNpc neurons and ∼62% of VTA
DA neurons, somewhat resembling previously published data.
Interestingly, in both human and mouse midbrain, ventral SNpc
DA neurons showed a stronger signal for DCC than DA neurons
in the dorsal SNpc and the VTA, suggesting that the DCC protein
level may distinguish between populations of DA neurons with
different vulnerability in both species. As with other investigated
candidates, it remains unclear if the expression pattern of DCC
is directly linked to the selective DA neuron vulnerability and
which pathways DCC may use to modulate the susceptibility of
DA neurons to degeneration.
MITOCHONDRIA AND ENERGY DEMAND
Several studies have investigated mitochondrial DNA deletions
in SNpc DA neurons in human postmortem midbrain tissue
samples. High levels of mitochondrial DNA deletions were found
in SNpc DA neurons from both aged controls and patients with
PD, while other brain regions were characterized by lower deletion
levels (Bender et al., 2006, 2008; Kraytsberg et al., 2006). A
recent study now compared mitochondrial DNA deletions in
aged human control SNpc and VTA DA neurons using LCM
followed by quantitative real-time PCR (Elstner et al., 2011). The
number of detected deletions was higher in SNpc DA neurons
than in VTA DA neurons, however, it is unclear if this difference
is a cause or rather a consequence of the differential vulnera-
bility observed among these two groups of neurons. Moreover,
although noradrenergic neurons in the locus coeruleus are often
more severely affected by degeneration in PD than SNpc DA
neurons (Zarow et al., 2003), they showed fewer mitochondrial
DNA deletions than SNpc and VTA DA neurons, suggesting that
either the number of mitochondrial DNA deletions are unrelated
to the selective vulnerability of DA and noradrenergic neurons, or
the vulnerability of noradrenergic neurons is regulated by factors
different from those that play a role for the vulnerability of SNpc
and VTA.
Using immunostaining, Liang et al. studied the intracellular
area that is occupied by mitochondria in various neurons in the
mouse brain and used these data to draw conclusions regarding
the mitochondrial mass (Liang et al., 2007). According to this
investigation, SNpc DA neurons have a lower mitochondrial mass
than VTA DA neurons, which might contribute to the selective
vulnerability of SNpc and VTA. However, SNpc DA neurons
appeared to have a similar mitochondrial mass as the much
more resistant midline DA neurons in the interfascicular nucleus,
and additional neuronal groups with a low mitochondrial mass
were identified outside the midbrain which raises the question
of how significantly the observed differences correlate with the
selective vulnerability of these neurons to degeneration. More-
over, it is entirely unclear if these findings translate to the human
brain.
Investigations addressing mitochondrial DNA deletions and
the mitochondrial mass are interesting, particularly in the light
of hypotheses arguing that the exceptionally high vulnerability
of SNpc DA neurons as compared to VTA DA neurons may
at least in part be due to their architecture and the resulting
metabolic needs. SNpc DA neurons are estimated to form much
larger axonal arbors and a higher number of synapses than VTA
DA neurons, which may result in the pronounced redistribution
of mitochondria to their axonal terminals and the tremendous
elevation of their demand for energy as well as their susceptibility
to insults jeopardizing the neuronal energy supply (Surmeier
et al., 2010; Bolam and Pissadaki, 2012). Moreover, a recent com-
putational analysis proposed that the unique architecture of SNpc
DA neurons leads to a higher need of energy for the propagation
of action potentials and the maintenance of the resting membrane
potential (Pissadaki and Bolam, 2013). Closely related to this
topic, a computational model for the degeneration of motor neu-
rons in ALS predicted a link between mitochondrial dysfunction,
the lack of ATP, prolonged depolarization and the disruption of
intraneuronal calcium levels (Le Masson et al., 2014). Although
very compelling, it needs to be pointed out that a significant
part of these suggestions is based on computational evidence
and not wet lab experiments. Actual comparative measurements
of the energy demand of SNpc and VTA DA neurons, studies
investigating and comparing the impact of axonal arborization on
the distribution of mitochondria between terminals and neuronal
cell bodies, and experiments providing direct evidence for a link
between the lack of energy and high intracellular calcium levels
have not been conducted to date.
AGING
As aging is the major risk factor for developing PD, some inves-
tigations focus on the comparison of the changes that occur in
SNpc and VTA DA neurons as a function of age, with the goal
of identifying factors that mediate the selective vulnerability of
midbrain DA neurons. Although interesting, this approach has
been characterized by limited success to date. Using immunofluo-
rescence staining of brain tissue obtained from young, middle-
aged and old-aged rhesus monkeys, a recent study investigated
the degree of nitrative damage in the midbrain DA neurons and
concluded that DA neurons in the ventral SNpc show the most
severe nitrative damage over time (Kanaan et al., 2008). Although
interesting, these data are rather reflective of the differential DA
vulnerability than providing an explanation for it. Gao et al.
dissected and collected SNpc or VTA from mice of different ages
and compared the molecular signature of the two brain regions
using microarray (Gao et al., 2013). Differentially expressed genes
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were identified and grouped into functional categories. These
results can serve as a database for follow-up studies that are
required to confirm some of the differentially expressed gene
candidates and to link their function to the selective vulnerability
of different groups of DA neurons in the midbrain.
ALDEHYDE DEHYDROGENASE 1
Many studies have now provided evidence that molecular dif-
ferences exist among SNpc DA neurons and among VTA DA
neurons, and the most recent investigations addressing this topic
have been discussed above. These data demonstrate that, within
the SNpc and the VTA, subgroups of DA neurons exist that can
be distinguished by subtle variations in their expression profiles.
Such findings may potentially explain why not all DA neurons
within the SNpc or the VTA demonstrate the same susceptibility
to degeneration in PD. Furthermore, on the electrophysiologic
level, Lammel et al. have shown that most VTA DA neurons are
functionally different from SNpc DA neurons, and that consider-
able heterogeneity exists, especially among the DA neurons in the
VTA (Lammel et al., 2008). However, an increasing body of evi-
dence suggests that electrophysiologic heterogeneity can also be
found among SNpc DA neurons. Activity recordings in monkeys
demonstrated that functional diversity can be observed among
SNpc DA neurons that project to different target regions, as not
all of these neurons exhibit the same response to motivational
stimuli (Matsumoto and Hikosaka, 2009). A different study in
anesthetized mice revealed that burst firing in vivo is gated by
ATP-sensitive potassium channels in some but not all SNpc DA
neurons (Schiemann et al., 2012), and experiments carried out
in mouse brain slices showed that some SNpc DA neurons are
capable of co-releasing dopamine and GABA, but only a select
subset of SNpc DA neurons has the capacity to do so (Tritsch et al.,
2012). The molecular determinants of most of these differences
and their potential relevance for the selective DA neuron vulner-
ability have not been identified to date. As discussed above, the
higher vulnerability of ventral SNpc DA neurons as compared to
dorsal SNpc DA neurons is one of the most well-known examples
for heterogeneity among SNpc DA neurons. Interestingly, two
studies in mice have demonstrated that aldehyde dehydrogenase
1 (ALDH1A1) is expressed in a subset of DA neurons, most of
which are located in the ventrolateral part of the SNpc (McCaffery
and Dräger, 1994; Liu et al., 2014). ALDH1A1 belongs to a group
of enzymes that catalyze the oxidation of aldehydes to carboxylic
acids. Aldehyde dehydrogenases such as ALDH1A1 presumably
oxidize and thereby detoxify 3,4-dihydroxyphenylacetaldehyde
(DOPAL), a reactive metabolite of dopamine (Marchitti et al.,
2007). The inhibition of aldehyde dehydrogenase and the accu-
mulation of DOPAL may contribute to the pathogenesis of PD
(Fitzmaurice et al., 2013). Liu et al. now described a connection
between the expression of ALDH1A1 and the vulnerability of DA
neurons to alpha-synuclein-mediated degeneration. The authors
focused their investigations on transgenic mice overexpressing
human mutant alpha-synuclein in the midbrain DA neurons,
resulting in moderate progressive DA neuron degeneration (Lin
et al., 2012). Using these mice, it was shown that ALDH1A1-
positive DA neurons in the ventral SNpc are more resistant to
degeneration and develop fewer alpha-synuclein aggregates than
ALDH1A1-negative SNpc DA neurons which are found in the
dorsomedial part of the SNpc. Although very interesting, these
findings are somewhat in contrast to the lower resistance of
ventral tier SNpc DA neurons than dorsal tier SNpc DA neurons
in PD (Kordower et al., 2013). ALDH1A1-positive VTA DA
neurons also showed a higher resistance to degeneration than
ALDH1A1-negative VTA DA neurons, indicating that ALDH1A1
is not a SNpc-specific susceptibility factor. Knockout of Aldh1a1
alone was not sufficient to induce DA cell loss, but facilitated DA
neuron degeneration in transgenic alpha-synuclein mice. Virus-
mediated overexpression of ALDH1A1 in midbrain cultures from
transgenic alpha-synuclein mice increased DA neuron survival.
ALDH1A1-mediated protection seemed specific to the alpha-
synuclein model and was not observed with the use of other
neurotoxins in vitro which could point to a specific role for
ALDH1A1 in diminishing alpha-synuclein-mediated toxicity. The
exact mechanism, however, is unclear. The ALDH1A1 expression
pattern in the midbrain was conserved between mice and humans.
In midbrain tissue from human controls, ALDH1A1 expression
was observed mainly in the ventral SNpc DA neurons. Tissue
samples from PD patients revealed extensive DA cell loss in
the ventral tier of the SNpc which seemed associated with the
reduced expression of ALDH1A1 in the remaining ventral tier
SNpc DA neurons at various disease stages. These data indicate
that ALDH1A1 may potentially have a protective function for
human SNpc DA neurons.
LEFT-RIGHT-ASYMMETRY
Last but not least, it is noteworthy that a number of studies discuss
a differential vulnerability of SNpc DA neurons in the left and
right hemispheres in PD. Many patients with PD demonstrate
a pronounced asymmetric manifestation of the cardinal motor
signs with one body side being more affected than the other
side, and this asymmetry can also be measured in studies that
image the DA system in PD patients using tracers (Djaldetti et al.,
2006). These findings suggest that the left and right hemispheres
contain a different number of SNpc DA neurons in these patients.
A correlation of the number of neuromelanin-positive neurons
in the SNpc bilaterally in post-mortem brain samples from PD
patients with the asymmetric clinical signs that had been docu-
mented for these individuals revealed that many but not all cases
showed the expected pattern of asymmetric cell loss (Kempster
et al., 1989). Additional studies comparing the number of SNpc
DA neurons in the left and right hemispheres in patients with PD
have not been published. It is not well understood if the observed
asymmetry is indeed due to the different vulnerability of left-
and right-sided SNpc DA neurons to degeneration, or to other
reasons including inborn, side-specific differences in the number
of SNpc DA neurons, unbalanced limb exercise, hand dominance
or the uneven, localized permeability of the blood brain barrier
to toxins (Djaldetti et al., 2006). If differential susceptibility of
the left and right SNpc to degeneration indeed plays a role, the
molecular basis has yet to be elucidated. Interestingly, several
asymmetric animal models have been developed recently, includ-
ing a monkey model that was generated by a unilateral surgical
lesion of the nigrostriatal pathway followed by systemic admin-
istration of MPTP, and a genetic DJ1 knockout mouse model
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(Blesa et al., 2011; Rousseaux et al., 2012). These models have the
potential to serve as tools to further study the molecular basis of
asymmetry in PD.
CONCLUSION
The elucidation of the molecular determinants that increase the
susceptibility of SNpc DA neurons or decrease the susceptibility
of VTA DA neurons to degeneration in PD is a very exciting
but challenging research area that holds great potential for the
development of novel therapeutic strategies for PD. The gene
expression signatures of SNpc and VTA DA neurons are extremely
similar to each other. Only a rather limited number of genes
within these two groups of neurons demonstrate differences in
their expression levels, and the differences are usually small to
moderate. Moreover, studies focusing on the identification and
characterization of differentially expressed proteins have revealed
that the candidate proteins identified to date are not exclusively
expressed in either SNpc or VTA DA neurons but rather enriched
in either neuronal group at best. Based on these findings, it
may be speculated that it is unlikely that only one or two key
proteins mediate the selective vulnerability of DA neurons in PD.
Instead, it is more likely that a cell type-specific combination of
several modest gene expression differences and subtle differences
in protein function are responsible for establishing the increased
or decreased midbrain DA neuron vulnerability. Although still
at the beginning, current research on mitochondria and energy
demand, the molecular underpinnings of electrophysiologic dif-
ferences between subtypes of DA neurons, and developmentally
expressed proteins that remain expressed in adult DA neurons
appears promising. Emphasis should be placed on the identi-
fication of molecular targets that increase the resistance of DA
neurons to degeneration. It is likely that multiple toxic factors
contribute to DA neuron degeneration, and it will be difficult to
slow down or halt cell loss by inhibiting only one or few of the
related pathways. However, boosting the function of proteins that
support the survival of SNpc DA neurons may provide a powerful
tool to improve DA neuron resistance to many of the toxic path-
ways associated with PD. The non-uniform expression patterns of
some proteins among SNpc as well as VTA DA neurons certainly
add another layer of complexity to the investigation of differential
DA neuron vulnerability. However, the careful consideration of
these differences and the correlation of the expression pattern of
these gene and protein candidates with the varying vulnerability
of DA neuron subgroups may provide additional opportunities
for the discovery of genes that play a role in the selective DA
vulnerability in PD.
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